NADMED as Business
NADMED has paying customers in 36 countries across four continents. We have made consistent progress in our target customer segments: clinical laboratories, pharma, drug development, and research markets. Both kit sales (NAD+, NADH, NADP, NADPH) and services (four NAD forms, two glutathiones) have generated strong interest. NADMED kits are manufactured in Germany and California, and our research lab is located in Helsinki, Finland.
NADMED has steadily grown its customer base among clinical laboratories, a segment estimated to become the company’s largest market. Currently, we serve the fields of neurology, oncology, mitochondrial and muscular diseases, fatigue, and Long COVID. We expect this list to expand to include many other diseases. We serve laboratories in the USA, UK, Germany, Spain, the Czech Republic, Thailand, Singapore, the UAE, and Finland, and we continue to add new territories.
The early mainstay of NADMED has been universities and other research institutions that have an immediate need for accurate, affordable, and scalable NAD measurement capability. This segment has shown healthy growth, with a growing customer base across Europe, the USA, and Asia.
The interest of pharmaceutical companies in NADMED stems from the novel capability to accurately and quickly measure the complete metabolic state of cells (the redox metabolites NAD+, NADH, NADP, NADPH, GSSG, and GSH). This is highly beneficial for drug development from many angles. The NADMED method saves time in metabolic assessment, reducing sample analysis time compared to mass spectrometry.